GlassScriptPhysician profile
Logan B Rogers
NPI 1710448972
$1,840.38
in general payments reported to CMS, 2019-2025
18 companies · $702 in 2025
The $702 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $406 · 2023: $174 · 2024: $402 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $277.05 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $218.42 | 2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $215.92 | 2022-2025 | Austedo Xr, Uzedy |
| Corium, LLC | $208.27 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $166.93 | 2024-2025 | Auvelity, Sunosi |
| Abbvie INC. | $129.07 | 2021-2024 | Vraylar |
| Alkermes, INC. | $126.67 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $121.82 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $85.17 | 2022-2025 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.05 | 2021-2024 | Caplyta |
| Lundbeck LLC | $59.44 | 2022-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $58.57 | 2024-2025 | Fanapt |
| Jazz Pharmaceuticals INC. | $31.04 | 2021 | |
| Indivior INC. | $17.85 | 2023 | Perseris |
| Neos Therapeutics, LP | $15.92 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $15.08 | 2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $14.25 | 2024 | Spravato |
| Noven Therapeutics, LLC | $13.86 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.